Immunhistochemical Expression of Estrogen, Progesteron Receptors, C-Erb B-2, P53 and BRCA1 in Ovarian Carcinoma and Their Prognostic Value

Yıl 2022, Cilt: 17 Sayı: 1, 121 - 129, 21.03.2022

Didar Gürsoy İclal Gürses Vedia Bennu Gilan Bahar Taşdelen Ali Arıcan Celalettin Tok

https://doi.org/10.17517/ksutfd.873338

Öz

Our study aimed to determine immunohistochemical expression of ER, PR, C-erbB-2, p53 and BRCA1 genes and their relationship with clinicopathological features and prognostic significance. The present study included 85 patients that were diagnosed with epithelial OC, treated and followed-up between 2002 and 2012 at Mersin University, Faculty of Medicine. Immunohistochemical expression of ER, PR, C-erbB-2, p53 and BRCA1 and their relation-ship with clinicopathological parameters were evaluated. In serous carcinomas, expression of ER was significantly associated with metastasis to the fallopian tube, expression of PR was significantly associated with patient’s age, expression of p53 was significantly associated with the progression-free survival (PFS), cytoplasmic expression of BRCA1 was significantly associated with the overall survival (OS) and PFS. In pathogenesis groups, 55 tumors were type 1, and 30 tumors were type 2. There were significant correlations with ER, PR and p53 expressions between the two groups. In our study, PR and p53 were prognostic factors in serous carcinoma. Extensive studies that contain more cases in each histological group are needed to determine the prognostic value of these five immunohistochemical markers.

Anahtar Kelimeler

ovarian cancer, hormone receptors, C-erb-B2, P53, BRCA1

Destekleyen Kurum

Mersin Üniversitesi, BAP bİRİMİ

Proje Numarası

BAP-TF CTB (DG) 2013-3 TU.

Teşekkür

We would present our thanks to Assistant Professor M. D. Huseyin Durukan from Mersin University, Department of Obstetrics and Gynecology for his precious contribution to our study.

Over Karsinomlarında Östrojen, Progesteron Reseptörleri, C-Erb B-2, P53 ve BRCA1’in İmmünhistokimyasal Ekspresyonu ve Prognostik Önemleri

Öz

Çalışmamız ER, PR, C-erbB-2, p53 ve BRCA1 genlerinin immünohistokimyasal ekspresyonunu ve bunların klinikopatolojik özellikler ve prognostik önemi ile ilişkisini belirlemeyi amaçlamaktadır. Çalışmamıza Mersin Üniversitesi Tıp Fakültesi'nde 2002-2012 yılları arasında epitelyal OK tanısı konulan ve takip edilen 85 hasta dahil edildi. ER, PR, C-erbB-2, p53 ve BRCA1'in immünohistokimyasal ekspresyonu ve bunların klinikopatolojik parametrelerle ilişkisi değerlendirildi. Seröz karsinomlarda, ER ekspresyonu fallop tüpüne metastaz ile, PR ekspresyonu hastanın yaşı ile anlamlı şekilde ilişkiliydi, p53 ekspresyonu progresyonsuz sağkalım (PFS) ile anlamlı şekilde ilişkilendirildi, BRCA1'in sitoplazmik ekspresyonu genel sağkalım (OS) ve PFS ile anlamlı şekilde ilişkiliydi. Patogenez gruplarında 55 tümör tip 1 ve 30 tümör tip 2 idi. İki grup arasında ER, PR ve p53 ekspresyonları ile anlamlı korelasyonlar vardı. Çalışmamızda PR ve p53 seröz karsinomda prognostik faktörlerdi. Bu beş immünohistokimyasal belirtecin prognostik değerini belirlemek için her histolojik grupta daha fazla vaka içeren kapsamlı çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

ovarian cancer, hormone receptors, C-erb-B2, P53, BRCA1

Proje Numarası

BAP-TF CTB (DG) 2013-3 TU.

Kaynakça

• Referans1-Boyle P, Levin B (eds) World cancer report 2008. World Health Organization, Lyon.
• Referans2-Seidmann JD, Ronnett BM, Shih LM, Cho KR, Kurman RJ. Surface Epithelial Tumors of the Ovary. Kurman R (eds). Blaustein’s Pathology of the Female Genital Tract, 7th edition. New York, Springer-Verlag, 2019:841-966.
• Referans3- Chan, J. K., Tian, C., Monk, B. J., Herzog, T., Kapp, D. S., Bell, J., & Young, R. C. (2008). Prognostic factors for high‐risk early‐stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer, 112(10), 2202-2210.
• Referans4-Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9(6):1980-1989.
• Referans5-Çalıkapan M. Meme kanserinde prognostik faktorlerin hastanemiz olgu serisindeki sağkalıma etkisi. Uzmanlık tezi, İstanbul, 2004.
• Referans6-Leong SYA, Cooper K, Leong WMJF. Manual of Diagnostic Antibodies for Immunohistol-ogy. London: Oxford University Pres. 1999;163-164, 283-284.
• Referans7-Sieh W, Köbel M, Longacre TA et al. Associations between hormone receptor expressin and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013 Aug;14(9):853-62.
• Referans8-Hogdall EVS, Christensen L, Hogdall CS et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep. 2007 Nov;18(5):1051-9.
• Referans9-Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes & development 2012;26:1268-1286.
• Referans10-Online Mendelian Inheritance in Man OM-NIoGM, Johns Hopkins University (Baltimore, MD). Tumor protein p53; TP53. 2013.
• Referans11-Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and con-tinuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006;10:501-514.
• Referans12-Lee YK, Park NH. Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecol Oncol. 2009 Mar;112(3):475-80.
• Referans13-Barh D, Gunduz M (2015-01-22). Noninvasive Molecular Markers in Gynecologic Can-cers. CRC Press. p. 427. ISBN 9781466569393.
• Referans14-Tangjıtgamol S, Ramirez PT, Sun CC et al. Expression of HER-2/neu, epidermal growth factor receptor,vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor,and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cer-vix: a clinicopathologic and prognostic study. Int J Gynecol Cancer, 2005;15:646-656.
• Referans15-Rosty C, Couturier JR, Salomon AV et al. Overexpression/amplification of HER–2/neu is uncommon in invasive carcinoma of the uterine cervix. Int J Gynecol Pathol, 2003;23:13–17.
• Referans16-Vaz FH, Machado PM, Brandao RD et al. Familial Breast/Ovarian Cancer and BRCA1/2 Genetic Screening: The Role of Immunhistochemistry as an Additional Method in the Selec-tion of Patients. Journal of Histochemistry&Cytochemistry 2007;55(11):1105-1113.
• Referans17-Elizabeth MHammond. H, Hayes DF. Mitch Dowsett; D. Craig Allred; Karen L. Hagerty; Sunil Badve;et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version). Arch Pathol Lab Med—Vol 134, July 2010.
• Referans18-Antonio C. Wolff, M. Elizabeth H. Hammond, David G. Hicks, Mitch Dowsett, Lisa M. McShane et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med-Vol 138, February 2014.
• Referans19-Lindgren PR, Cajander S, Bäckström T, Gustafsson JA, Mäkelä S, Olofsson JI. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol. 2004 Jun 30;221(1-2):97-104.
• Referans20-Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, Saito S.Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma. Am J Surg Pathol. 2001 may;25(5).667-72.
• Referans21-DiCioccio RA, Werness BA, Peng R, Allen HJ, Piver MS. Correlation of TP53 mutations and p53 expression in ovarian tumors. Cancer Genet Cytogenet. 1998 Sep;105(2):93-102.
• Referans22-Skırnısdottır I, Sorbe B, Seıdal T. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011 “”Aug;21(6):1024-31.
• Referans23-McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011 Aug; 43(5):420-432.
• Referans24-Hogdall EVS, Christensen L, Kjaer SK et al. Distribution of HER-2 Overexpression in Ovarian Carcinoma Tissue and Its Prognostic Value in Patients with Ovarian Carcinoma. CANCER July 1, 2003/Volume 98/Number1.
• Referans25-Berchuck A, Kamel A, Whitaker R, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990;50:4087-4091.
• Referans26-De Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wis-man GB, de Bock GH, de Vries EG, de Jong S, van der Zee AG. The ErbB signalling path-way: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008; 99:341-349.
• Referans27-Saxena R, Dwivedi A. ErbB family receptor inhibitors as therapeutic agents in breast can-cer: current status and future clinical perspective. Med Res Rev. 2012; 32:166-215.
• Referans28-Buller RE, Anderson B, Connor JP, Robinson R. Familial ovarian cancer. Gynecol Oncol. 1993;51:160-166.
• Referans29-Broet SC, Bessard AC, Tourmeau AL et al. HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Annals of Oncology ,2004;15:104-112.
• Referans30-Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA. BRCA1 expres-sion in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2006 Jan-Feb;16.
• Referans31-Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008 Apr 15;68(8):2581-6.
• Referans32-Deloia J, Krivak T, Krivak T, Darcy K. BRCA1 expression and improved survival in ovari-an cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncolo-gy Group Stud. British Journal of Cancer (2013) 108, 1231–1237